Temozolomide (Temodar)

descriptionPublicationkeyboard_double_arrow_right Article 10 Jun 2010 English Publisher:American Society of Neuroradiology (ASNR)Journal:American Journal of Neuroradiology, volume 31, pages 1,383-1,384 (issn: 0195-6108, eissn: 1936-959X,

Copyright policy )

Authors: J R, Wesolowski; P, Rajdev; S K, Mukherji;

doi: 10.3174/ajnr.a2170

pmid: 20538821

pmc: PMC7966084

Temozolomide (Temodar)

- Summary
- Subjects
- Metrics

Abstract

Temozolomide, an oral alkylating agent, is a commonly used medicine in the treatment of anaplastic astrocytoma and glioblastoma multiforme. This paper will present the mechanism of action as well as the clinical role for this chemotherapeutic drug.

Related Organizations

University of Michigan–Flint
United States

Keywords

Dacarbazine, Brain Neoplasms, Temozolomide, Administration, Oral, Humans, Astrocytoma, Glioblastoma, Antineoplastic Agents, Alkylating, Drug Costs

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	85
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 1%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%